Current Problems in Cancer: Case Reports (Jun 2022)

Rare solid and cystic presentation of hemangiopericytoma/ solitary fibrous tumor: A case report

  • Heather N. Hayenga,
  • Chunyu Cai,
  • David Fetzer,
  • Sarah White,
  • Joshua Kuban,
  • Zabi Wardak,
  • Robert S. Benjamin,
  • Edward Pan,
  • James Strauss,
  • Boning Gao,
  • John Minna,
  • Javier Martin-Broto,
  • J Louis Hinshaw

Journal volume & issue
Vol. 6
p. 100149

Abstract

Read online

Hemangiopericytoma/Solitary Fibrous Tumor (HPC/SFT) is a rare fibroblastic sarcoma characterized by hyper-vasculature and STAT6 trans-nuclear localization. Cystic HPC/SFT is extremely rare. Due to the scarcity of cystic HPC/SFT cases, diagnostic and treatment guidelines are not well established. To our knowledge, we present the first case of cystic HPC/SFT observed in the liver. In addition, the patient had over 6 years of recurrent hypervascular solid HPC/SFT in the brain, bone, leptomeninges, liver and lung prior to developing a cystic HPC/SFT. Briefly, a 37-year-old Caucasian female with a history of HPC/SFT presented with several enlarging cystic hepatic lesions on surveillance MRI. The cystic/nonenhancing nature of these liver metastases were confirmed by contrast-enhanced ultrasound. Due to diagnostic uncertainty, two of these hepatic cysts were removed laparoscopically and pathology confirmed cystic HPC/SFT with a high MIB-1 index. Previously, in 2014, the patient was diagnosed with solid intracranial grade III pseudopapillary mesenchymal HPC/SFT in the posterior fossa and underwent subtotal resection followed by external beam radiation. In 2017, she had recurrent intracranial, vertebral, and intraspinal intradural extramedullary HPC/SFTs followed by surgery, proton therapy, and SRS radiotherapy. In 2019, after an uneventful pregnancy and birth, routine surveillance revealed metastases in the liver requiring an extended right hepatectomy. In 2020-2021 two solid hypervascular hepatic HPC/SFT were found and treated with microwave ablation. Shortly afterwards, several rapidly growing hepatic cystic HPC/SFT lesions developed. Of note, she has not taken any systemic therapy, indicating the cystic tumors are from metastases rather than cystic degradation as a sequela of therapy. Overall, this case highlights that cystic metastasis are a potential clinical manifestation of solid HPC/SFT. Moreover, cystic HPC/SFT can co-exist with the more typical primary solid hypervascular HPC/SFTs in the same patient. Lastly, in this case cystic HPC/SFT had a higher growth rate and propensity to metastasize as compared to the solid equivalent.

Keywords